drugset / Trial / NCT00836485

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

NCT00836485

Phase 2 Completed 122 enrolled Senju USA, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase 2 study that will consist of 4 visits over a 5 week period. Drug will be evaluated using the conjunctival allergen challenge model of allergic conjunctivitis.

Timeline

Start
2009-02
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketotifen Small molecule 4 % Other
Comparator Olopatadine Other / unclassified 0.2 % Other

Indications